How to Get Dayvigo (Lemborexant) in New York

Dayvigo is the FDA-approved brand name for lemborexant, an oral dual orexin receptor antagonist (DORA) used to treat insomnia in adults. It is not the same drug as suvorexant (Belsomra) or daridorexant (Quviviq), the two other DORAs on the US market, though all three work by the same mechanism. Getting a prescription filled in New York involves three separate questions that are easy to blur together: whether a clinician is legally allowed to prescribe it to you, whether your insurer will pay for it, and whether a pharmacy near you stocks it. The first is a stable, well-documented fact. The second and third change by plan, by year, and sometimes by pharmacy, and neither should be taken as settled without a direct check at the time you need the prescription.

What Dayvigo is and what it is FDA-approved to treat

Lemborexant blocks orexin-A and orexin-B, wake-promoting neuropeptides, rather than acting on GABA receptors the way older sedative-hypnotics such as zolpidem do. The FDA approved lemborexant in December 2019 for insomnia in adults characterized by difficulty falling asleep, staying asleep, or both, according to the FDA-approved prescribing information.

The pivotal phase 3 trials that supported approval compared lemborexant against placebo, and one arm also included an active comparator, over roughly one month, with a long-term extension study following patients further. Those trials reported improvement in both sleep-onset and sleep-maintenance measures relative to placebo. The exact numeric effect sizes reported in different summaries of this trial program vary, and a reader who wants a precise number (minutes of sleep-onset reduction, percentage improvement in wake after sleep onset) should verify it against the primary trial publication rather than treat any single restated figure as authoritative.

Lemborexant carries a federal Schedule IV controlled-substance classification, indicating lower abuse potential than Schedule II or III agents. This classification is what allows it to be prescribed through telehealth in states, including New York, that permit remote prescribing of Schedule IV medications.

Lemborexant (Dayvigo) is FDA-approved for adult insomnia and is legally prescribable by any New York-licensed MD, DO, NP, or PA who holds a valid DEA registration, including through a telehealth visit, because it is a Schedule IV rather than Schedule II or III drug. Whether a specific insurance plan covers it without prior authorization, and what it costs in cash, are separate questions that depend on the individual plan and change over time, and neither is established by the drug's FDA approval or schedule status.

Who can prescribe it in New York

Physicians, nurse practitioners, and physician assistants with an active New York DEA registration for Schedule IV substances can write a lemborexant prescription. New York has expanded independent prescribing authority for nurse practitioners who meet the state's practice-hour threshold, and physician assistants generally prescribe within a collaborative arrangement with a supervising physician. Because scope-of-practice rules are set and occasionally revised at the state level, a patient who is specifically choosing a provider type (for example, deciding whether an NP visit will suffice) should confirm current requirements with the New York State Education Department's Office of the Professions rather than relying on a fixed date cited here.

A sleep medicine specialist is not required to start Dayvigo. Primary care physicians, psychiatrists, and geriatricians commonly prescribe DORAs. Referral to a sleep specialist is more appropriate when there is suspected obstructive sleep apnea (OSA) or narcolepsy, both of which change the risk-benefit calculation for an orexin-pathway drug.

Telehealth prescribing of Dayvigo in New York

New York permits telehealth prescribing of Schedule IV controlled substances through a real-time video visit that establishes a valid prescriber-patient relationship. In practice, this typically means a synchronous video appointment during which the prescriber takes a sleep history, screens for narcolepsy and severe hepatic impairment, checks for interacting medications (particularly strong CYP3A inhibitors), and then sends the prescription electronically to a pharmacy of the patient's choosing.

The time from an initial telehealth appointment to a filled prescription depends heavily on whether the insurer requires prior authorization. Some platforms also apply their own internal protocol requiring a documented trial of a non-drug approach, such as cognitive behavioral therapy for insomnia (CBT-I), before prescribing a controlled sedative-hypnotic. That is a clinic-level or payer-level policy choice, not a New York state law requirement, and it varies by platform and by plan.

What actually needs to be checked at the point of care versus what is already settled

This is the distinction that matters most for a New York patient trying to plan around cost and timing, and it is the one most geographic access pages skip.

Verification checklist: stable facts versus facts that require a current check

Stable (federal law, FDA label, or long-standing clinical practice; unlikely to differ by New York county or change month to month)

• Lemborexant is FDA-approved for adult insomnia and is not indicated for children, per the FDA-approved label.
• It is a federal Schedule IV controlled substance.
• The FDA label does not require routine baseline lab testing before starting it.
• Severe hepatic impairment is a contraindication; moderate impairment requires the lower 5 mg dose per the label.
• Concurrent use of a strong CYP3A inhibitor is contraindicated; moderate CYP3A inhibitors require dose limitation.
• Zolpidem (Ambien) carries an FDA boxed warning for complex sleep behaviors that lemborexant's label does not carry in the same form, per the FDA-approved zolpidem labeling.

Needs a current, dated check before you rely on it (varies by plan, pharmacy, or changes over time)

• Whether your specific insurance plan requires prior authorization for Dayvigo, and what step-therapy trial (commonly a generic like zolpidem) it demands first. Call the number on your insurance card or check the plan's current formulary document.
• Whether New York Medicaid's managed-care plan or fee-for-service program requires prior authorization for lemborexant this year, and what documentation it wants. This changes with formulary updates and should be confirmed with the specific Medicaid plan.
• Cash price if uninsured. Brand-name Dayvigo without insurance is expensive relative to generic sedative-hypnotics; get a same-day quote from the filling pharmacy rather than relying on a published estimate, since cash prices shift.
• Whether a manufacturer savings card applies to your situation (commercial insurance generally qualifies; federal health program enrollees such as Medicare Part D typically do not, under federal anti-kickback rules). Confirm current terms directly with the manufacturer program.
• Whether a specific retail pharmacy near you has it in stock. Chain pharmacies commonly carry FDA-approved branded sedative-hypnotics, but stock varies by store, especially outside major metro areas.
• Current telehealth platform-specific requirements (for example, a mandated CBT-I trial before prescribing), since these are set by individual practices, not by state law.
• Turnaround time from prescription to fill, which depends on whether prior authorization is triggered and how quickly your specific insurer processes it.

If you cannot verify lemborexant coverage details from a primary source (your current insurance policy, your pharmacy, or your prescriber's office), any figures cited for it, including those from earlier versions of this page, should be considered unconfirmed and not relied upon for planning purposes.

Prior authorization and cost, in general terms

Commercial and Medicaid managed-care plans commonly place brand-name DORAs like Dayvigo on a non-preferred tier that triggers prior authorization, and typically ask the prescriber to document an insomnia diagnosis, a failed or contraindicated trial of a preferred agent (often generic zolpidem), and consideration of non-drug therapy such as CBT-I. This is a general description of how step-therapy and prior-authorization programs are usually structured, not a statement of any specific New York plan's current rule, and it should be confirmed with the plan before a patient assumes a particular outcome.

If a prior authorization is denied, plans generally offer an appeal process, and some states set turnaround-time requirements for standard versus urgent authorization requests. Because these turnaround rules and their enforcement can change, a patient facing a denial should ask the plan directly for its current appeal timeline rather than relying on a fixed number.

Pharmacy access and controlled-substance transfers

Retail chain pharmacies, independent pharmacies, and mail-order pharmacies in New York can all fill a lemborexant prescription, subject to individual stock and formulary placement. A 503A compounding pharmacy can prepare a patient-specific lemborexant formulation, for example a different dosage form for someone who cannot swallow tablets, under an individualized prescription and New York State Board of Pharmacy oversight; a compounded product cannot be produced in bulk for general distribution the way the FDA-approved tablet is.

Federal controlled-substance regulation allows a Schedule III-V prescription, which includes lemborexant, to be transferred between pharmacies, with additional flexibility when both pharmacies share a real-time database. A patient relocating to New York with remaining refills on an out-of-state lemborexant prescription can generally ask the receiving New York pharmacy to contact the originating pharmacy to initiate a transfer; if no refills remain, a new prescription from a New York-licensed prescriber, obtainable through telehealth, is the more direct path.

Evaluation before starting: what is required and what is judgment

The FDA label does not mandate blood work or a sleep study before starting lemborexant. A reasonable clinical evaluation still typically includes a sleep history, screening for obstructive sleep apnea (for example with a STOP-BANG questionnaire), an assessment of hepatic function status, a review of concurrent medications for CYP3A interactions, and a basic substance-use screen, consistent with standard practice for prescribing any Schedule IV hypnotic. This is site- and clinician-level judgment layered on top of the label, not a separate New York legal requirement.

Orexin-pathway drugs have a documented, still-evolving evidence base regarding their effect on sleep architecture in patients who also have obstructive sleep apnea. A recently published response to commentary specifically addressed lemborexant's effect on sleep architecture in participants with insomnia and mild OSA, reflecting active scientific discussion rather than settled guidance (Kärppä et al. response, 2025). In practice, most prescribers screen for OSA before starting lemborexant and use clinical judgment, sometimes with sleep-medicine input, when OSA is confirmed or suspected. New York has numerous accredited sleep centers and home sleep testing is widely available if that evaluation is needed.

Dosing and what to expect

The labeled starting dose is 5 mg taken orally once nightly, within 30 minutes of intended bedtime, with at least 7 hours of sleep opportunity remaining, with an option to increase to 10 mg if the lower dose is tolerated but not sufficiently effective. No dose above 10 mg is approved. Individualized dosing decisions, including whether to increase the dose or how to taper if discontinuing, should be made with the prescribing clinician rather than adjusted independently.

Somnolence is the most commonly reported adverse effect of DORAs relative to placebo across recent comparative analyses of insomnia pharmacotherapies, though the exact magnitude reported differs somewhat between analyses and should not be quoted as a single fixed percentage without checking the specific source (2025 network meta-analysis of insomnia drug adverse events). Patients should avoid alcohol and other CNS depressants while on lemborexant and should be counseled about the possibility of next-morning grogginess, particularly early in treatment, given the drug's longer elimination half-life relative to short-acting hypnotics.

How lemborexant compares to other insomnia medications available in New York

New York prescribers have access to the standard FDA-approved insomnia formulary plus off-label options:

• Suvorexant (Belsomra): also a DORA, approved earlier than lemborexant. A 2025 systematic review and network meta-analysis compared the comparative efficacy and safety of daridorexant, lemborexant, and suvorexant directly, and is a more reliable source for head-to-head comparison than older single-trial comparisons (Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant, 2025). No claim from that analysis should be restated here as a specific number without the reader or clinician checking the paper directly, since network meta-analysis results are sensitive to which trials and doses are included.
• Zolpidem (Ambien): a GABA-A receptor modulator, available generically and inexpensively, which is why many prior-authorization pathways require a documented zolpidem trial before approving a DORA. It carries an FDA boxed warning for complex sleep behaviors such as sleepwalking and sleep-driving, per the FDA-approved zolpidem labeling.
• Trazodone: prescribed off-label for insomnia, without FDA approval for that indication and with less controlled-trial support at the low doses typically used for sleep. It is inexpensive and not a controlled substance, which is why it is often tried early in step-therapy protocols.

Choosing among these depends on whether the primary complaint is sleep onset, sleep maintenance, or both, prior treatment failures, comorbidities such as OSA or hepatic disease, and cost or coverage constraints. This decision belongs with a prescriber who knows the patient's full history, not with a general access guide.

What is established, what is plausible, and what is not established

Established: lemborexant is FDA-approved for adult insomnia, is a Schedule IV controlled substance, and can legally be prescribed in New York by appropriately licensed clinicians including through telehealth. The FDA label's contraindications and dosing rules (hepatic impairment, CYP3A interactions, 5 mg/10 mg dosing) are fixed facts of the current label.

Plausible but not settled by a single trial: the precise comparative advantage of lemborexant over suvorexant or over generic hypnotics for a given patient, and the drug's optimal role in patients with mild, untreated OSA. Recent network meta-analyses and correspondence are actively working through these questions, and conclusions may shift as more comparative data accumulate.

Not established by anything in this article: any specific New York insurer's current prior-authorization policy, this year's Medicaid formulary tier for Dayvigo, a specific cash price, or which named pharmacy chain has it in stock in a given county. Those facts are volatile by nature and must be confirmed directly at the time of the visit.

If sleep problems are severe, associated with breathing pauses witnessed by a partner, accompanied by chest pain, or accompanied by suicidal thoughts, that warrants urgent evaluation rather than a routine insomnia prescription pathway.